LungLife AI, Inc. (AIM:LLAI)

Market Cap	1.27M
Revenue (ttm)	22.95K
Net Income (ttm)	-3.53M
Shares Out	30.66M
EPS (ttm)	-0.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,431,628
Average Volume	504,084
Open	4.250
Previous Close	4.250
Day's Range	3.136 - 5.000
52-Week Range	0.800 - 21.700
Beta	0.37
RSI	72.73
Earnings Date	May 22, 2025

About LungLife AI

LungLife AI, Inc., a diagnostic company, researches and develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology in the United States and the People’s Republic of China. The company engages in developing LungLB, a blood-based test to stratify cancerous and benign lung nodules identified by CT scan. The company was formerly known as Cynvenio Biosystems, Inc. and changed its name to LungLife AI, Inc. in May 2019. LungLife AI, Inc. was incorporated in 2009 and is based in Thousand Oaks, California.

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 2009
• Employees: 15
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: LLAI

Financial Performance

In 2023, LungLife AI's revenue was $46,000, an increase of 91.67% compared to the previous year's $24,000. Losses were -$5.41 million, -28.83% less than in 2022.

Financial numbers in USD